跳到主要內容

臺灣博碩士論文加值系統

(44.210.85.190) 您好!臺灣時間:2022/12/10 14:32
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

: 
twitterline
研究生:連捷
研究生(外文):LIAN,JIE
論文名稱:γδT細胞的培養與增生
論文名稱(外文):The Culture of γδT Cells
指導教授:林俊銘林俊銘引用關係
指導教授(外文):LIN,JUN-MING
口試委員:林俊銘應靜雯陳雲翔
口試委員(外文):LIN,JUN-MINGYING,JING-WENCHEN,YUN-XIANG
口試日期:2015-06-30
學位類別:碩士
校院名稱:東吳大學
系所名稱:微生物學系
學門:生命科學學門
學類:微生物學類
論文種類:學術論文
論文出版年:2015
畢業學年度:103
語文別:中文
論文頁數:66
中文關鍵詞:被動免疫療法培養人類γδT 細胞
外文關鍵詞:γδT cellsProliferationIPPimmunotherapy
相關次數:
  • 被引用被引用:0
  • 點閱點閱:190
  • 評分評分:
  • 下載下載:3
  • 收藏至我的研究室書目清單書目收藏:0
將特定的細胞在體外大量增生後,注射回到病人的體內以對抗癌症是一種新興的免疫療法(被動免疫療法)。此種療法的一大重點是需要選擇特定的細胞,例如自然殺手細胞(Natural killer cell,NK cell)。而γδT細胞則被認為是具有抗癌潛力的細胞,因此我們嘗試以γδT細胞為此種免疫療法的目標,但是γδT細胞要在此種療法上實用則會遭遇到一些困難,其中最大的困難便是體外培養的不易與體內γδT細胞的稀少。為了克服這個首要的障礙,我們嘗試改良其培養條件,與選殖γδT細胞受體,轉植至表現載體,使其能夠在其他較易培養的細胞上表現。而在選擇培養條件的同時也考量PD-1之表現,最後與目前臨床治療所使用的條件相比較,得出能在短時間內大量增生γδT細胞,又同時能使PD-1表現較現行方法為低的培養條件。
There is a rising immunotherapy that proliferate the immune cells in vitro then inject back to patients. Particular cells are needed, such as natural killer cells. γδT cells are suggested to have potential to against sort of cancers. So we tried to use these cells in the immunotherapy. γδT cells still have some obstacles in application for immunotherapy because γδT cells are difficult to proliferate alone ex vivo. To overcome the barrier, we tried to improve their cultural condition and clone the γδT cell receptor. Compare with the clinical cultural condition and consider about the expression of Program cell death-1, we found a better cultural condition that can proliferate γδT cells in a short time with a lower expression of PD-1.
中文摘要………………………………………………………………..…6
英文摘要………………………………………..…………………………7
壹、 前言 …………………………………………………….………….8
貳、 文獻回顧……………………………………………………..……10
一、 免疫療法………………………………..…………………..10
二、 非專一性免疫細胞………………………………………....11
三、 γδT細胞…………………………………………… ……..12
四、 基因轉殖…………………………………………… ……..13
五、 免疫抑制…………………………………………… ……..13
六、 臨床治療…………………………………………… ……..14
參、研究目的…………………………………..………………………..15
肆、實驗架構…………………………………………………………….16
伍、材料與方法………………………………………………………….17
陸、實驗結果…………………………………..………………………..30
柒、討論…………………………………..…………… ………………..34
捌、參考文獻………………………………………………………….…38
玖、圖表…………………………………..………………………………42

1.Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. Journal of immunotherapy (Hagerstown, Md : 1997) 2003, 26(4): 332-342.

2.Legut M, Cole DK, Sewell AK. The promise of gammadelta T cells and the gammadelta T cell receptor for cancer immunotherapy. Cellular & molecular immunology 2015.

3.Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer immunology, immunotherapy : CII 2008, 57(11): 1599-1609.

4.Liakou CI, Narayanan S, Ng Tang D, Logothetis CJ, Sharma P. Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer immunity 2007, 7: 10.

5.Pan K, Guan XX, Li YQ, Zhao JJ, Li JJ, Qiu HJ, et al. Clinical activity of adjuvant cytokine-induced killer cell immunotherapy in patients with post-mastectomy triple-negative breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2014, 20(11): 3003-3011.

6.Siegers GM, Ribot EJ, Keating A, Foster PJ. Extensive expansion of primary human gamma delta T cells generates cytotoxic effector memory cells that can be labeled with Feraheme for cellular MRI. Cancer immunology, immunotherapy : CII 2013, 62(3): 571-583.

7.Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Molecular therapy : the journal of the American Society of Gene Therapy 2013, 21(4): 904-912.

8.Perico N, Casiraghi F, Introna M, Gotti E, Todeschini M, Cavinato RA, et al. Autologous mesenchymal stromal cells and kidney transplantation: a pilot study of safety and clinical feasibility. Clinical journal of the American Society of Nephrology : CJASN 2011, 6(2): 412-422.

9.Thevenot PT, Sierra RA, Raber PL, Al-Khami AA, Trillo-Tinoco J, Zarreii P, et al. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors. Immunity 2014, 41(3): 389-401.

10.Bernsmeier C, Pop OT, Singanayagam A, Triantafyllou E, Patel VC, Weston CJ, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK. Gastroenterology 2015, 148(3): 603-615 e614.

11.Robertson-Tessi M, El-Kareh A, Goriely A. A model for effects of adaptive immunity on tumor response to chemotherapy and chemoimmunotherapy. Journal of theoretical biology 2015.

12.Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(8): 3005-3010.

13.Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010, 28(19): 3167-3175.

14.Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system. Nature immunology 2015, 16(4): 343-353.

15.Meeh PF, King M, O'Brien RL, Muga S, Buckhalts P, Neuberg R, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer immunology, immunotherapy : CII 2006, 55(9): 1072-1080.

16.Viey E, Laplace C, Escudier B. Peripheral gammadelta T-lymphocytes as an innovative tool in immunotherapy for metastatic renal cell carcinoma. Expert review of anticancer therapy 2005, 5(6): 973-986.

17.Olive C, Allen AC, Harper SJ, Wicks AC, Feehally J, Falk MC. Expression of the mucosal gamma delta T cell receptor V region repertoire in patients with IgA nephropathy. Kidney international 1997, 52(4): 1047-1053.

18.Kobayashi H, Tanaka Y, Yagi J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer immunology, immunotherapy : CII 2001, 50(3): 115-124.

19.Sicard H, Ingoure S, Luciani B, Serraz C, Fournie JJ, Bonneville M, et al. In vivo immunomanipulation of V gamma 9V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. Journal of immunology 2005, 175(8): 5471-5480.

20.Dieli F, Poccia F, Lipp M, Sireci G, Caccamo N, Di Sano C, et al. Differentiation of effector/memory Vdelta2 T cells and migratory routes in lymph nodes or inflammatory sites. The Journal of experimental medicine 2003, 198(3): 391-397.

21.Lang JM, Kaikobad MR, Wallace M, Staab MJ, Horvath DL, Wilding G, et al. Pilot trial of interleukin-2 and zoledronic acid to augment gammadelta T cells as treatment for patients with refractory renal cell carcinoma. Cancer immunology, immunotherapy : CII 2011, 60(10): 1447-1460.

22.Salot S, Laplace C, Saiagh S, Bercegeay S, Tenaud I, Cassidanius A, et al. Large scale expansion of gamma 9 delta 2 T lymphocytes: Innacell gamma delta cell therapy product. Journal of immunological methods 2007, 326(1-2): 63-75.

23.Allen SJ, Hamrah P, Gate D, Mott KR, Mantopoulos D, Zheng L, et al. The Role of LAT in Increased CD8+ T Cell Exhaustion in Trigeminal Ganglia of Mice Latently Infected with Herpes Simplex Virus 1. Journal of virology 2011, 85(9): 4184-4197.

24.Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer cell 2005, 8(5): 369-380.

25.Lertworapreecha M, Patumraj S, Niruthisard S, Hansasuta P, Bhattarakosol P. Cytotoxic function of gamma delta (gamma/delta) T cells against pamidronate-treated cervical cancer cells. Indian journal of experimental biology 2013, 51(8): 597-605.




QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top